Evidence map›Paper›PMID 38233591›Full record

ArticleScientific reports2024

Advancing tuberculosis diagnosis and management in cynomolgus macaques using Xpert MTB/RIF ultra assay.

Prapaporn Srilohasin, Saradee Warit, Therdsak Prammananan, Saijai Smithtikarn, Reka Kanitpun, Mutchamon Kaewparuehaschai, Kirana Noradechanon, Suthirote Meesawat, Nattakan Thakaew, Nonthakorn Sakulwittayasuk and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Biofilm Associated Persistence and Drug Tolerance in Mycobacteria Within Host Microenvironments.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2026
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Prapaporn SrilohasinDepartment of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Saradee WaritNational Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Khlong Luang, Thailand.
Therdsak PrammanananDrug Resistant Tuberculosis Research Fund, Siriraj Foundation, Bangkok, Thailand.
Saijai SmithtikarnDivision of Tuberculosis, Department of Disease Control, Ministry of Public Health, Bangkok, Thailand.
Reka KanitpunNational Institute of Animal Health, Bangkok, Thailand.
Mutchamon KaewparuehaschaiDepartment of National Parks, Wildlife and Plant Conservation, Chachoengsao, Thailand.
Kirana NoradechanonDepartment of National Parks, Wildlife and Plant Conservation, Chachoengsao, Thailand.
Suthirote MeesawatNational Primate Research Center of Thailand-Chulalongkorn University, Saraburi, Thailand.
Nattakan ThakaewDrug Resistant Tuberculosis Research Fund, Siriraj Foundation, Bangkok, Thailand.
Nonthakorn SakulwittayasukDrug Resistant Tuberculosis Research Fund, Siriraj Foundation, Bangkok, Thailand.
Taratorn KemthongNational Primate Research Center of Thailand-Chulalongkorn University, Saraburi, Thailand.
Tanapat PalagaDepartment of Microbiology, Faculty of Science, Chulalongkorn University, Bangkok, Thailand.
Suchinda MalaivijitnondNational Primate Research Center of Thailand-Chulalongkorn University, Saraburi, Thailand.
Angkana ChaiprasertDrug Resistant Tuberculosis Research Fund, Siriraj Foundation, Bangkok, Thailand. angkana.cha@mahidol.ac.th.
Chulalongkorn University · THSiriraj Hospital · THNational Science and Technology Development Agency · THMinistry of Public Health · TH

Funding

NSRF through the Program Management Unit for Human Resources & Institutional Development, Research and Innovation B05F640122
6 · The paper itself

Abstract

The detection and management of Mycobacterium tuberculosis complex (MTBC) infection, the causative agent of tuberculosis (TB), in macaques, including cynomolgus macaques (Macaca fascicularis), are of significant concern in research and regions where macaques coexist with humans or other animals. This study explored the utility of the Xpert MTB/RIF Ultra assay, a widely adopted molecular diagnostic tool to diagnose tuberculosis (TB) in humans, to detect DNA from the Mycobacterium tuberculosis complex in clinical samples obtained from cynomolgus macaques. This investigation involved a comprehensive comparative analysis, integrating established conventional diagnostic methodologies, assessing oropharyngeal-tracheal wash (PW) and buccal swab (BS) specimen types, and follow-up assessments at 3-month, 6-month, and 12-month intervals. Our results demonstrated that the Xpert MTB/RIF Ultra assay was able to detect MTBC in 12 of 316 clinical samples obtained from cynomolgus macaques, presenting a potential advantage over bacterial culture and chest radiographs. The Xpert MTB/RIF Ultra assay exhibited exceptional sensitivity (100%) at the animal level, successfully detecting all macaques positive for M. tuberculosis as confirmed by traditional culture methods. The use of PW samples revealed that 5 positive samples from 99 (5.1%) were recommended for testing, compared to 0 samples from 99 buccal swab (BS) samples (0.0%). In particular, the definitive diagnosis of TB was confirmed in three deceased macaques by MTB culture, which detected the presence of the bacterium in tissue autopsy. Our findings demonstrate that the implementation of the Xpert MTB/RIF Ultra assay, along with prompt isolation measures, effectively reduced active TB cases among cynomolgus macaques over a 12-month period. These findings highlight the advance of the Xpert MTB/RIF Ultra assay in TB diagnosis and its crucial role in preventing potential outbreaks in cynomolgus macaques. With its rapidity, high sensitivity, and specificity, the Xpert MTB/RIF Ultra assay can be highly suitable for use in reference laboratories to confirm TB disease and effectively interrupt TB transmission.

Indexed as

Antibiotics, AntitubercularMycobacterium tuberculosisTuberculosisTuberculosis, PulmonaryAnimalsDrug Resistance, BacterialHumansMacaca fascicularisRifampinSensitivity and SpecificitySputumAntibiotics, AntitubercularRifampin

Identifiers

PMID38233591
PMCPMC10794203
OpenAlexW4390942866

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.